Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemaphor, a biotechnology research and development company, has appointed Paul Dick as its new CEO. Dr Dick replaces Graham Burton who will continue as president of the company.
Subscribe to our email newsletter
Dr Dick holds a veterinary degree with advanced training in infectious diseases and immunology. He has held positions of responsibility over nearly 20 years with two multinational pharmaceutical companies including COO of Naturagen Health Solutions, within Elanco, a division of Eli Lilly and Company.
David Hankinson, chairman of the board of Chemaphor, said: “On behalf of the board of directors, I am pleased that Paul is joining our team. We believe that the leadership, management and technical skill set that Paul brings to Chemaphor complements the capabilities of our senior management group and will help accelerate our progress to market.”
Dr Burton said: “We believe that Paul’s technical capabilities, business acumen and dynamic style are exactly what are needed to help unlock the potential of Chemaphor’s technology in the field of carotenoid oxidation products. Paul has world class knowledge, contacts and practical experience in the key focus areas for Chemaphor and we are very excited as to how far his drive, leadership and insight will take us.”